BIVI - BioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer's Disease at CTAD | Benzinga
CARSON CITY, Nev., Oct. 19, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that blinded data on cognitive, biomarker, and imaging findings from the recently completed Phase 3 clinical trial (NCT04669028) of NE3107 in the treatment of mild to moderate Alzheimer's Disease will be presented during an oral presentation at the upcoming 16th Clinical Trials on Alzheimer's Disease (CTAD), to be held in Boston, MA from October 24-27, 2023.
The presentation Clinical Outcomes From a Phase 3, Randomized, Placebo-Controlled Trial of NE3107 in Subjects With Mild to Moderate Probable Alzheimer's Disease (Christopher Reading1, Clarence Ahlem1, Joseph Palumbo1, Nily Osman1, Marcia Testa 2, Donald Simonson3) will be presented on Wednesday October 25 at 12:20pm.
The Company has monitored blinded data as they become available throughout the trial to assess patient safety and support timely data entry into the official statistical analysis database. Interim blinded data was previously presented at other scientific congresses to provide a glimpse of the characteristics of the enrolled subjects at the start of the trial, and the upcoming presentation at CTAD will provide blinded data at the end of the trial from subjects whose data are currently available for analysis.
Details of the presented data and conclusions will be announced once the presentations are made public at the conference.
The last patient came in for the last treatment ...